Publications by authors named "S Chamberlain"
Background: Pandemic-related restrictions in nursing homes have undermined the critical role that family and friend caregivers play in enhancing resident quality of life.
Objective: We examined how family caregiver access restrictions in nursing homes were implemented and how they impacted the mutual well-being of and relationships between residents and their caregivers over time. s Between March 2021 and march 2022, 24 'designated caregivers' in Atlantic Canada were interviewed three times.
Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis.
Lancet Psychiatry
January 2025
Background: The comparative benefits and harms of available interventions for ADHD in adults remain unclear. We aimed to address these important knowledge gaps.
Methods: In this systematic review and component network meta-analysis (NMA), we searched multiple databases for published and unpublished randomised controlled trials (RCTs) investigating pharmacological and non-pharmacological interventions for ADHD in adults from database inception to Sept 6, 2023.
Article Synopsis
- Clinical guidelines for medications treating gambling disorder are unclear, prompting a network meta-analysis to compare their efficacy and tolerability.
- The study reviewed 22 randomized controlled trials, ultimately analyzing 16 with nearly 1,000 participants, focusing on gambling symptom severity and quality of life as efficacy outcomes.
- Nalmefene showed the most promise in reducing gambling severity and improving quality of life, although it and naltrexone had higher dropout rates due to side effects, indicating lower tolerability compared to placebo.
Background: Schizophrenia is considered to have a lifetime prevalence of around 1%. Up to 30% of patients diagnosed with schizophrenia are subsequently categorised as treatment resistant. Current guidelines advise against the use of antipsychotic polypharmacy (APP) or high-dose antipsychotic therapy (HDAT) in the treatment of schizophrenia; however, these treatment approaches continue to be used in up to 25% of cases.
View Article and Find Full Text PDF